2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-17412AS
    Minocycline-d6 1036070-10-6 98%
    Minocycline-d6 is deuterium labeled Minocycline (HY-17412A). Minocycline is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect.
    Minocycline-d6
  • HY-174267S
    ATX-IN-2 3076224-81-9 98%
    ATX-IN-2 (Compound 25) is an orally active and potent ATX inhibitor with an IC50 value of 3.27 nM. ATX-IN-2 reduces lysophosphatidic acid (LPA) secretion. ATX-IN-2 is promising for research of ATX-mediated diseases, such as inflammation, pulmonary fibrosis.
    ATX-IN-2
  • HY-17453S1
    Salmeterol-13C6 xinafoate 98%
    Salmeterol-13C6 (xinafoate) is the 13C6 labeled Salmeterol (xinafoate). Salmeterol (GR 33343X) xinafoate is a potent and selective human β2 adrenoceptor agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHO cells expressing human β2, β1 and β3 adrenoceptors with pEC50s of 9.6, 6.1, and 5.9, respectively.
    Salmeterol-13C6 xinafoate
  • HY-17461AR
    Cortisone acetate (Standard) 50-04-4 99.39%
    Cortisone acetate (Standard) is the analytical standard of Cortisone acetate. This product is intended for research and analytical applications. Cortisone acetate (Cortisone 21-acetate), an oxidized metabolite of Cortisol (a Glucocorticoid). Cortisone acetate acts as an immunosuppressant and anti-inflammatory agent. Cortisone acetate can partially intervene in binding of Glucocorticoid to Glucocorticoid-receptor at high concentrations.
    Cortisone acetate (Standard)
  • HY-17461S4
    Cortisone-d9
    Cortisone-d9 (17-Hydroxy-11-dehydrocorticosterone-d9) is the deuterium labeled Cortisone (HY-17461). Cortisone (17-Hydroxy-11-dehydrocorticosterone), an oxidized metabolite of Cortisol (a Glucocorticoid). Cortisone acts as an immunosuppressant and anti-inflammatory agent. Cortisone can partially intervene in binding of Glucocorticoid to Glucocorticoid-receptor at high concentrations.
    Cortisone-d9
  • HY-17463S1
    Prednisolone-d6 98%
    Prednisolone-d6 is the deuterium labeled Prednisolone (HY-17463). Prednisolone is a potent, orally active corticosteroid and a glucocorticoid. Prednisolone possesses about four times the anti-inflammatory activity of hydrocortisone while causing less salt and water retention. Prednisolone can be used for ocular, anti-inflammatory research.
    Prednisolone-d6
  • HY-17463S3
    Prednisolone-d4-1 115397-50-7
    Prednisolone-d4-1 is the deuterium labeled Prednisolone (HY-17463). Prednisolone is a potent, orally active corticosteroid and a glucocorticoid. Prednisolone possesses about four times the anti-inflammatory activity of hydrocortisone while causing less salt and water retention. Prednisolone can be used for ocular, anti-inflammatory research.
    Prednisolone-d4-1
  • HY-17474AS
    Parecoxib-d5 sodium 98%
    Parecoxib-d5 sodium is the deuterium labeled Parecoxib sodium. Parecoxib Sodium (SC 69124A) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib Sodium can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.
    Parecoxib-d5 sodium
  • HY-17479AR
    Amfenac Sodium Hydrate (Standard) 61618-27-7
    Amfenac (Sodium Hydrate) (Standard) is the analytical standard of Amfenac (Sodium Hydrate). This product is intended for research and analytical applications. Amfenac Sodium Hydrate is a COX-2 inhibitor.
    Amfenac Sodium Hydrate (Standard)
  • HY-17492S1
    Zafirlukast-13C,d3 2140305-18-4 98%
    Zafirlukast-13C,d3 is the 13C- and deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.
    Zafirlukast-13C,d3
  • HY-17492S2
    Zafirlukast-13C,d6 98%
    Zafirlukast-13C,d6 is the 13C- and deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.
    Zafirlukast-13C,d6
  • HY-174990A
    HW201877 enantiomer 2927452-82-0
    HW201877 enantiomer is the enantiomer of HW201877 (HY-174990) and is 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitor with an IC50 of 12.2 nM. HW201877 enantiomer can be used for the research of inflammatory bowel disease, idiopathic pulmonary fibrosis, ulcerative colitis, and Crohn's disease.
    HW201877 enantiomer
  • HY-17507AR
    Pantoprazole sodium (Standard) 138786-67-1
    Pantoprazole (sodium) (Standard) is the analytical standard of Pantoprazole (sodium). This product is intended for research and analytical applications. Pantoprazole sodium (BY10232 sodium) is an orally active and potent proton pump inhibitor (PPI). Pantoprazole sodium, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole sodium improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole sodium significantly increased tumor growth delay combined with Doxorubicin (HY-15142).
    Pantoprazole sodium (Standard)
  • HY-17507BR
    Pantoprazole sodium hydrate (Standard) 164579-32-2 98%
    Pantoprazole (sodium hydrate) (Standard) is the analytical standard of Pantoprazole (sodium hydrate). This product is intended for research and analytical applications. Pantoprazole sodium hydrate (BY10232 sodium hydrate) is an orally active and potent proton pump inhibitor (PPI). Pantoprazole sodium hydrate, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole sodium hydrate improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole sodium hydrate significantly increased tumor growth delay combined with Doxorubicin (HY-15142).
    Pantoprazole sodium hydrate (Standard)
  • HY-17507S1
    Pantoprazole-d3 922727-37-5 98%
    Pantoprazole-d3 is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI). Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142).
    Pantoprazole-d3
  • HY-175310S
    Voderdeucitinib 2824164-00-1 98%
    Voderdeucitinib (Compoudn I) is a TYK2 inhibitor with an anti-inflammatory activity. Voderdeucitinib can be used for inflammatory and autoimmune disease research, such as rheumatoid arthritis (RA), multiple sclerosis and intestinal bowel disease (IBD).
    Voderdeucitinib
  • HY-17569S2
    Difluprednate-d3-1
    Difluprednate-d3-1 is the deuterium labeled Difluprednate (HY-17569). Difluprednate is a glucocorticoid receptor (GC receptor) agonist with a Ki of 0.78 nM. Difluprednate's active metabolite 21-deacetylated difluprednate (DFB) is a competitive agonist of GC receptors with a Ki of 0.061 nM. Difluprednate binds to GC receptors through metabolism to DFB, regulating the transcription of inflammatory mediator genes, thereby exerting anti-inflammatory activity. Difluprednate can be used for research related to ocular inflammation, such as postoperative inflammation, anterior uveitis, etc.
    Difluprednate-d3-1
  • HY-17618AS
    Rac-Pemafibrate-13C,d3
    Rac-Pemafibrate-13C,d3 (Rac-K13675-13C,d3) is the deuterium and 13C-labeled Rac-Pemafibrate (HY-17618A). Pemafibrate racemate (K13675 racemate) is the racemate of pemafibrate, and activates PPARα activity, with EC50s of 1 nM, >10 μM and 1.7 μM for h-PPARα, h-PPARγ and h-PPARδ, respectively.
    Rac-Pemafibrate-13C,d3
  • HY-176277S
    Fibrinopeptide B, human-(Val-13C5,15N, Arg-13C6,15N4) TFA
    Fibrinopeptide B, human-(Val-13C5,15N, Arg-13C6,154) TFA is the 13C- and 15N-labeled Fibrinopeptide B, human (HY-P1493). Fibrinopeptide B, human is a 14-aa peptide, released from the amino-terminus of β-chains of fibrinogen by thrombin.
    Fibrinopeptide B, human-(Val-13C5,15N, Arg-13C6,15N4) TFA
  • HY-17627S1
    Avacopan-d4 2316781-85-6
    Avacopan-d4 (CCX168-d4) is the deuterium labeled Avacopan (HY-17627). Avacopan (CCX168) is a potent, selective and orally available complement 5a receptor (C5aR) inhibitor with an IC50 of 0.1 nM.
    Avacopan-d4
Cat. No. Product Name / Synonyms Application Reactivity